Drawing for DERMACYTE

USPTO serial 87693641

DERMACYTE

Reviewed by CopyMark Law Group

Reg. 5507644Status 702Registered
Filing date
Status date
Registration date
Jul 3, 2018
Examiner
SMITH, BRIDGETT G
Law office
TMO LAW OFFICE 115

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with DERMACYTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Karen M. Hahn

Karen M. Hahn HAHN LAW FIRM8311 BRIER CREEK PARKWAY; SUITE 105277RALEIGH, NC 27617UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Human biological amniotic membrane tissue intended for subsequent implantation; human biological amniotic tissue derived from postpartum tissues that may include amniotic membrane, amniotic fluid, umbilical cord, or placenta, intended for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; human biological tissue, namely, blood, stem cells, umbilical cords and placentas for use in biological tissue grafts for use in surgery and wound repair; topical treatment in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; topical treatment made from amniotic material in the nature of a wound dressing for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; topical treatment made from amniotic material in the nature of an allograft for medical use for the treatment of wounds, ulcers, burns, scars and surgical incisions; wound treatment in the nature of amniotic material prepared in sheet forms or flowable formsACTIVENov 8, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 1, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Feb 1, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Feb 1, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 10, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Jul 3, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 25, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 3, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 17, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 17, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 28, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 14, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 6, 2018DOCKASSIGNED TO EXAMINER—
Dec 4, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 24, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance